Table 1.
Baseline demographics and characteristics of 6306 patients in the safety analysis set
| Characteristics | Overall n = 6306 |
|---|---|
| Women | 2592 (41.1) |
| Age (y) | 74.5 ± 10.1 (median 76.0) |
| <70 | 1715 (27.2) |
| ≥70 to <75 | 1189 (18.9) |
| ≥75 to <80 | 1220 (19.3) |
| ≥80 to <85 | 1231 (19.5) |
| ≥85 to <90 | 729 (11.6) |
| ≥90 | 222 (3.5) |
| Weight (kg) (n = 5896) | 59.6 ± 12.6 (median 59.0) |
| ≤60 | 3282 (52.0) |
| >60 | 2614 (41.5) |
| Unknown | 410 (6.5) |
| Serum creatinine (mg/dL) (n = 5820) | 0.90 ± 0.37 |
| <1.5 | 5597 (88.8) |
| ≥1.5 | 223 (3.5) |
| Unknown | 486 (7.7) |
| Creatinine clearance (mL/min) (n = 5552) | 62.2 ± 26.8 |
| <15 | 4 (0.1) |
| ≥15 to <30 | 382 (6.1) |
| ≥30 to ≤50 | 1590 (25.2) |
| >50 to ≤80 | 2426 (38.5) |
| >80 | 1150 (18.2) |
| Unknown | 754 (12.0) |
| Past history | |
| Clinically important hemorrhage | 221 (3.5) |
| Congenital or acquired hemorrhagic disease | 102 (1.6) |
| Gastrointestinal ulcer | 147 (2.3) |
| Ischemic stroke and transient ischemic attack | 1101 (17.5) |
| Comorbidity | |
| Hypertension | 3855 (61.1) |
| Heart failure | 1921 (30.5) |
| Diabetes mellitus | 1121 (17.8) |
| Renal disorder | 930 (14.7) |
| Liver disorder | 771 (12.2) |
| Apixaban dosage | |
| 5 mg twice daily | 3600 (57.1) |
| 2.5 mg twice daily | 2694 (42.7) |
| Othersa | 12 (0.2) |
| Antiplatelet drug useb | 1184 (18.8) |
Note: Values are mean ± standard deviation or number (%) of patients.
a
See text for details.
b
Antiplatelet drugs that were used during the apixaban dosing period.